Background/Objective: To investigate the effect of soy protein containing isoflavones on homocysteine (Hcy), C-reactive protein (CRP), soluble E-selectin (sE-selectin), soluble vascular adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1). Subject/Methods: In a randomized crossover design, 34 postmenopausal women consumed soy protein isolate (2675 g protein containing 4478 mg isoflavones per day) or milk protein isolate (2675 g protein per day) for 6 weeks each. Fasting blood samples were collected at the end of each diet period and end points analyzed by enzyme-linked immunosorbent assay. Results: Concentrations of Hcy, CRP, sE-selectin, sVCAM-1 and sICAM-1 were not different between soy and milk diet treatments. Results did not differ by equol production status or by baseline lipid concentration. Adjustment for intake of folate and methionine did not alter the Hcy results. Conclusions: These data suggest that decreasing vascular inflammation and Hcy concentration are not likely mechanisms by which soy consumption reduces coronary heart disease risk.
Introduction
Consumption of soy foods has been associated with a reduced risk of coronary heart disease (CHD) in women (Zhang et al., 2003) . However, the cardiovascular risk factors altered by soy consumption and mechanisms involved have yet to be conclusively established. Historically, the majority of research has focused on soy and plasma lipids, but as the paradigm of atherogenesis has shifted from a disease of simple lipid accumulation to a complex condition of chronic inflammation and vascular dysfunction, additional risk factors (that is, homocysteine (Hcy) and markers of vascular inflammation) have emerged as potential targets for soy.
Elevated concentrations of Hcy (Boushey et al., 1995; Ridker et al., 1999) , C-reactive protein (CRP) (Ridker et al., 1998 (Ridker et al., , 2000 and vascular adhesion molecules (Hwang et al., 1997; Ridker et al., 2000) such as soluble E-selectin (sEselectin), soluble vascular adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1) have been associated with increased risk of CHD. Estrogen replacement therapy and the selective estrogen receptor modulator (SERM) raloxifene lower plasma Hcy (Walsh et al., 2000; Yildirir et al., 2002) . Estrogen, but not raloxifene, increases circulating CRP concentration (de Valk-de Roo et al., 1999; Walsh et al., 2000; Yildirir et al., 2002) by increasing hepatic production of CRP (Walsh et al., 2001; Skouby et al., 2002) . Both estrogen and raloxifene have been reported to decrease vascular adhesion molecules (Koh et al., 1999; Blum et al., 2000) by binding to estrogen receptors on the vascular endothelium and modulating transcription of these adhesion molecules (Caulin-Glaser et al., 1996) . Soy isoflavones are capable of binding to the estrogen receptor and have a similar affinity for the b-isoform (predominant form in vascular tissue) as estradiol (Gruber et al., 2002) . By mimicking the effect of a SERM, soy isoflavones may favorably alter Hcy, CRP and adhesion molecules. The isoflavone metabolite equol possesses higher affinity than its precursor daidzein (Gruber et al., 2002) ; therefore, the ability to produce equol (present in one-third of the population) may result in an augmented effect (Lampe et al., 1998; Xu et al., 2000; Setchell et al., 2002) . In addition to the isoflavones, soy protein contains other components, such as phytate and soy peptides, which may also exert an effect on CHD risk factors.
The hypothesis of this study was that consumption of isoflavone-containing soy protein isolate would alter these CHD risk factors in a pattern resembling the actions of a SERM, that is, a decrease in Hcy, sE-selectin, sVCAM-1 and sICAM-1 without an increase in CRP, and that these alterations would be amplified in equol producers.
Subjects and methods

Study design
The present study was part of a larger project investigating the effects of soy and probiotic consumption on plasma lipids, hormones and isoflavones in postmenopausal women with and without a history of breast cancer Nettleton et al., 2004 Nettleton et al., , 2005 . The principal study incorporated four 6-week diet treatments separated by 2-week washout periods in a randomized crossover design; the length of the washout was considered adequate for preventing residual effects protein isolate or probiotics on subsequent diet treatments while maximizing subject retention in the study. Samples representing the diet periods with probiotic consumption were not included in the present analysis of inflammation markers and Hcy. Participants were free-living and consumed their habitual diets supplemented by soy or milk protein isolate (both by Solae, St Louis, MO, USA). Soy and milk protein isolates were distributed relative to body weight and provided 0.38 g protein per kg body weight per day (2675 g day À1 isoflavones expressed as aglycone equivalents). Subjects were instructed to consume their daily allotment of protein powder divided in two doses; suggested uses for the powder were mixing with water, juice, milk, hot cocoa or adding to soft foods such as oatmeal. The importance of substituting the powder mixture for other foods to avoid weight gain was emphasized. In addition, subjects were required to exclude soy food products, flaxseed, alcoholic beverages, herbal or isoflavone supplements, and vitamin/mineral supplements containing greater than 100% of the daily value for any nutrient from their habitual diet and to limit intake of legumes to a single serving per week. Subjects recorded their powder consumption and any deviations from study restrictions on individualized calendars.
Subjects
The 34 subjects included in this study were obtained via a pool of postmenopausal women recruited from the Minneapolis/St Paul metropolitan area by local newspapers and community advertisement. Respondents were screened by telephone, in-person interview, and health assessment to verify they met the following inclusion criteria: absence of menstrual bleeding for past 12 months, follicle-stimulating hormone concentration 435 IU l
À1
, no hormonal therapy (hormone replacement, raloxifene, topical progesterone cream, steroids, thyroid replacement) or oral antibiotics within the past 3 months, no current use of hypocholesterolemic agents, body mass index 18-36 kg m
À2
, weight change o6.8 kg during past year and no current tobacco use. The study was approved by the Institutional Review Boards of the University of Minnesota and the US Army Medical Research and Materiel Command. All subjects gave written informed consent before participating in the study.
Data collection and analysis
Fasting blood samples were drawn between 0600 and 1000 hours on day 1 of the first diet period (baseline) and at the completion of each diet period. Blood for serum was drawn into tubes containing gel clot activator, incubated at room temperature for 10-30 min and centrifuged for 10 min at 4 1C and 2000 g. Blood for plasma Hcy was drawn into tubes containing EDTA, centrifuged at 15 1C and 2000 g for 10 min, and aprotinin and sodium azide added to final concentrations of 1 mg l À1 and 1 g l
À1
, respectively. Blood for plasma isoflavones was drawn into tubes containing heparin, centrifuged at 15 1C and 2000 g for 10 min and sodium azide and ascorbic acid added to final concentrations of 1 g l À1 each. All aliquots were frozen at À70 1C until analysis. Before the isoflavone assays, designated plasma was thawed, divided into aliquots and lyophilized for analysis.
Serum samples were analyzed in duplicate in a single run for sE-selectin, sVCAM-1 and sICAM-1 using enzyme-linked immunosorbent assays (R&D Systems, Minneapolis, MN, USA). Intra-assay variability was 5, 6 and 3%, respectively. Serum samples for CRP were analyzed in duplicate in a single run using enzyme-linked immunosorbent assay (ALPCO Diagnostics, Windham, NH, USA). Intra-assay variability was 5%. All samples from each subject were assayed in duplicate on the same day for plasma total Hcy using enzyme-linked immunosorbent assays (Diazyme Laboratories, San Diego, CA, USA). Intra-assay variability was 4% and interassay variability was 13%.
Plasma isoflavones (genistein, daidzein, equol and Odesmethylangolensin) were analyzed by competitive timeresolved fluoroimmunoassay as described previously (Wang et al., 2000; L'Homme et al., 2002; Brouwers et al., 2003) . Intraassay variability was 6.3, 7.1 and 8.1% and interassay variability was 9.5, 9.9 and 15.2% for genistein, daidzein and equol, respectively. Plasma O-desmethylangolensin was analyzed in a single batch with intra-assay variability of 15.8%.
Subjects collected three 24-h urine samples on the final 3 days of each diet treatment; volume of each collection was recorded, sodium azide added to a final concentration of 1 g l À1 and samples frozen at À20 1C. Before urinary equol analysis, urine was thawed, pooled proportionally for a 3-day sample, aliquoted and lyophilized for equol quantification. Urinary equol was analyzed by competitive time-resolved fluoroimmunoassay and a gas chromatography-mass spectrometry conversion factor applied to these values as described previously (Brouwers et al., 2003) .
Subjects completed detailed diet records for the 3 days before the first diet period (baseline) and for the final 3 days of each diet period. Food records were analyzed using Nutritionist V version 2.1 (First DataBank, Inc., Hearst Corporation, San Bruno, CA, USA).
Statistical analysis
Statistical analysis was performed with SAS version 8.2. (SAS Institute Inc., Cary, NC, USA) and SPSS version 12.0 (SPSS Inc., Chicago, IL, USA). Differences in Hcy and inflammation markers between soy and milk treatments and the interactions of treatment with equol production status (high/low), baseline lipid status (hypercholesterolemic/normocholesterolemic) and plasma isoflavone group (above/below median) were assessed with repeated measures analysis of variance with group as a between-subjects factor. Paired t-tests were used to compare energy, nutrient and isoflavone intake between soy and milk treatments. Pearson's correlation coefficients were calculated to determine the association between total plasma isoflavone concentration and soy-milk difference for all variables. Spearman's correlation coefficients were used to assess the relationship between urinary and plasma equol. Data are presented as means7standard deviation (s.d.). P-values less than 0.05 were considered significant.
Results
Subjects
There were no differences in baseline characteristics or response to diet treatment between women with and without a history of breast cancer; therefore, these groups were combined for all analyses. Baseline characteristics of the 34 subjects included in this study are shown in Table 1 . Twentytwo women (65%) were considered hypercholesterolemic (total cholesterol, TC45.18 mmol l
À1
). Based on subject written records, telephone and in-person conversations with subjects, and changes in plasma isoflavone concentrations, adherence to the study protocol was good. The protein isolates were well tolerated, as assessed by responses to nonleading questions at study visits and mid-period telephone conversations.
Dietary intake
There were no differences in energy or macronutrient intake between soy and milk diet treatments based on 3-day food records completed during the study (Table 2) . However, as a result of the inherent differences in soy and milk protein isolates, folate intake was higher during the soy treatment and methionine intake was higher during the milk treatment. Adjusting values of Hcy for these differences did not alter the results; therefore, unadjusted means are reported for all variables.
Equol production Based on visual identification of a clear demarcation in the urinary and plasma isoflavone data, high-equol producers were defined as women with plasma equol concentration415 nmol l À1 and urinary equol excretion41500 nmol day À1 while consuming the soy treatment. Plasma and urinary equol concentrations were highly correlated (r ¼ 0.75, Po0.0001) and both methods of classification established the same subjects as high producers. Six women (18%) in the present study were considered high-equol producers and twenty-eight women low-equol producers.
Hcy and inflammatory markers Hcy, CRP, sE-selectin, sVCAM-1 and sICAM-1 were not different between soy and milk treatments (Table 3 ). There was no interaction between baseline lipid status (hyper vs normocholesterolemic) and treatment for any variable (P ¼ 0.285-0.930). Likewise, there was no effect of equol production status on response to the intervention (Hcy 9.39 vs 10.54, P ¼ 0.622; CRP 2.73 vs 3.98, P ¼ 0.162; sE-selectin 34.6 vs 39.3, P ¼ 0.408; sVCAM-1 825 vs 815, P ¼ 0.900; sICAM-1 216 vs 206, P ¼ 0.634 for low equol producers compared to high equol producers during soy diet).
In a post hoc analysis, subjects were divided into two groups based on plasma isoflavone concentration (above or below the median concentration of 508 nmol l À1 ). There was a significant interaction (P ¼ 0.046) between plasma isoflavone group and diet on Hcy concentration (Table 4 ). The differences in Hcy between soy and milk treatments were in opposite directions for subjects above and below the median and were correlated with total plasma isoflavone concentrations (r ¼ À0.348; P ¼ 0.044). However, this partitioning of subjects did not influence the results of diet on CRP, sE-selectin, sVCAM-1 or sICAM-1. Total plasma isoflavone concentration was not correlated with the difference between soy and milk treatments for CRP or adhesion molecules.
Discussion
The results of this investigation suggest that while soy isoflavones do not produce estrogen's proinflammatory increase in CRP, neither do they exert an anti-inflammatory effect on vascular adhesion molecules. With the exception of one study reporting an improvement in CRP (Hall et al., 2005) , a preponderance of recently published studies administering soy protein isolate or isolated isoflavones concur with the absence of effect on CRP shown in the present study (Teede et al., 2004; D'Anna et al., 2005; Hilpert et al., 2005; Yildiz et al., 2005; Hanson et al., 2006; RyanBorchers et al., 2006) . Regardless of intervention length (1 month to 3 years), vehicle of administration (soy protein isolate or isoflavone tablets) or isoflavone dose (10-129 mg), significant effects on CRP were not observed in these studies. Although a low-saturated fat diet including soy foods, plant sterols, viscous fiber and nuts demonstrated a significant decline in CRP (Jenkins et al., 2003) , an intervention incorporating only the soy foods did not result in a reduction (Jenkins et al., 2002a) , suggesting that soy was not responsible for the decrease in CRP. Collectively, these studies suggest that soy isoflavones do not mimic the effect of estrogen on hepatic CRP-synthesis and are neutral to CRP concentrations. Although the majority of published investigations have failed to find a decrease in sVCAM-1 (Blum et al., 2003; Steinberg et al., 2003; West et al., 2005) , sICAM-1 (Blum et al., 2003; Steinberg et al., 2003; Hall et al., 2005) and sE-selectin (Blum et al., 2003; Steinberg et al., 2003; Hall et al., 2005) following isoflavone consumption, several investigations have reported a change. A 3-year study conducted with female monkeys receiving 19% of kilocalorie as soy protein and the equivalent of 129 mg isoflavones found a significant decrease in sVCAM-1 but no change in sE-selectin (Register et al., 2005) . Eight weeks of an isoflavone-enriched cereal bar resulted in decreased VCAM-1 in postmenopausal women with the AA genotype for ERb AluI but not for other genotypes (Hall et al., 2005) . After consuming a 40 mg isoflavone tablet b.i.d. for 6 weeks, subjects receiving tablets with high-formononetin (a precursor of daidzein) but not biochanin (a precursor of genistein) content experienced a significant decrease in sVCAM-1 compared to placebo (Teede et al., 2003) . Isoflavones in tablet form (57 mg b.i.d. for 3 months) resulted in a decrease in sE-selectin after both placebo and isoflavone but no difference between placebo and active treatments (Nikander et al., 2003) . However, when subjects were stratified based on plasma daidzein and genistein concentrations, women with isoflavone concentrations above the median exhibited a significant decrease while those below showed no change (Nikander et al., 2003) .
The mixed results of these investigations of isoflavones and adhesion molecules highlight several important issues that may influence study outcomes: duration, dose and isoflavone bioavailability/bioactivity. The present study and the three studies reporting no effects (Blum et al., 2003; Steinberg et al., 2003; West et al., 2005) were relatively short (6 weeks); it is possible a longer duration is required for a decrease to be observed. These studies similarly incorporated B25 g day À1 of isoflavone-rich soy protein; a higher dose may be needed to achieve the threshold plasma isoflavone concentration for an effect on adhesion molecules. For example, the median concentrations of isoflavones (particularly daidzein) in the study with concentration-dependent results (Nikander et al., 2003) were substantially higher than in the present study (daidzein 861 vs 74 nmol l
À1
; genistein 363 vs 238 nmol l
). This observation (Nikander et al., 2003) , in conjunction with the effect observed with formononetin-rich but not biochanin-rich tablets (Teede et al., 2003) suggests that daidzein may be the primary isoflavone responsible for modulating adhesion molecules. Alternatively, ability to convert daidzein to equol could be a factor in the effectiveness of the formononetin-rich preparation; however, in the present study as well as two others with results divided by equol production (Steinberg et al., 2003; West et al., 2005) , no differences were found in the responses of equol producers compared with nonproducers.
Although the present study did not find an effect of soy consumption on plasma Hcy concentration in all subjects combined, when subjects were divided based on total plasma isoflavone concentration, soy consumption tended to decrease Hcy in subjects with isoflavone concentrations above the median. This suggests that differences in isoflavone bioavailability among subjects may influence the effect of soy on Hcy. Results of similar Hcy investigations have not been published stratified by plasma isoflavone concentration to refute or support this theory. However, studies reporting a change in Hcy (Puska et al., 2002; Tonstad et al., 2002) provided 2-to 3-fold higher isoflavone doses than those without a significant effect (D'Anna et al., 2005; Roughead et al., 2005; Reimann et al., 2006) . While these investigations suggest a potential role for isoflavones in lowering Hcy, a recent study manipulating soy protein content of both isoflavones and phytate contradicts this theory (Hanson et al., 2006) . In this study of postmenopausal women, soy protein with native phytate levels reduced Hcy concentrations regardless of isoflavone level, suggesting phytate instead of isoflavones as the responsible component (Hanson et al., 2006) .
Another alternative explanation for the potential Hcylowering effect of soy is the lower methionine content of soy protein (1.3 g per 100 g protein) compared with milk protein (3.3 g per 100 g). This may be particularly pertinent for studies employing high intakes of protein (30-50 g) (Puska et al., 2002; Tonstad et al., 2002; Jenkins et al., 2002b) in which Hcy concentrations increased during milk protein consumption but did not change during soy consumption, resulting in a significant difference between soy and milk (Puska et al., 2002; Tonstad et al., 2002) . This hypothesis would also account for the lack of effect observed with 54 mg genistein supplementation (D'Anna et al., 2005) , 50 mg of isoflavones isolated from soy (Reimann et al., 2006) and substitution of 25 g soy protein for meat protein (Roughead et al., 2005) as these studies did not include a soy vs milk protein comparison.
Finally, the plasma lipid concentrations of subjects may explain variability in Hcy response to soy consumption; soy may be more likely to influence Hcy in subjects with elevated low-density lipoprotein cholesterol (LDL-C) concentrations. Although the baseline TC and LDL-C concen-trations of subjects in the present study were not related to the effect of soy on Hcy, these subjects were normo-or mildly hypercholesterolemic with a mean LDL-C of 3.46 mmol l
. In contrast, the baseline LDL-C concentrations in studies demonstrating a significant effect of soy on Hcy were substantially elevated at 4.56, 5.08 and 4.77 mmol l À1 (Puska et al., 2002; Tonstad et al., 2002; Jenkins et al., 2002b) . In hypercholesterolemia, the Hcy content of lipoproteins is proportionally higher than in a normocholesterolemic environment (Olszewski and McCully, 1991) . Soy protein consumption increases LDL receptor expression (Baum et al., 1998; Lovati et al., 2000) and removal of Hcycontaining lipoproteins from the plasma and may thereby augment the decrease in Hcy.
The present study examined the response of CHD risk factors (CRP, sE-selectin, sVCAM-1, sICAM-1 and Hcy) to a dose of isoflavone-rich soy protein deemed effective for decreasing plasma lipids by the FDA health claim (FDA, 1999) . Although the majority of relevant published studies are in agreement with the lack of significant effects reported here, the current study was limited in several ways. The isoflavone content of the soy treatment was lower than that achievable through isolated isoflavone supplements and may not have been sufficient to exert a therapeutic effect. The subjects were apparently healthy and exhibited concentrations of the plasma/serum markers generally within the normal ranges. The diet consumed by the subjects was not overtly atherogenic and in fact approximated the American Heart Association Step I diet. These details may have decreased the potential for observing significant changes. In addition, the number of equol producers was small, limiting the ability to detect differences between producers and nonproducers.
This study demonstrated that the incorporation of a moderate dose of isoflavone-containing soy protein isolate into a generally healthy diet does not decrease Hcy (except in subjects exhibiting higher concentrations of plasma isoflavones), CRP or the vascular adhesion molecules sEselectin, sICAM-1 or sVCAM-1. Several recent studies confirm the lack of effect with this level of soy protein/ isoflavones, although the possibility of a favorable effect at higher (pharmacologic) intakes does exist. Further research is needed to support or refute the ability of higher doses to impact Hcy, CRP and vascular adhesion molecules, and elucidate the responsible mechanisms. Until additional research corroborates the isolated findings of decreased Hcy, CRP or adhesion molecules, health professionals and health conscious adults should implement other approaches to modify these CHD risk factors.
